ed with patients in the lowest quarters for both biologic markers," the researchers found. "Level of sVCAM-1 was similarly predictive of ischemic stroke in patients allocated to placebo and perindopril-based (blood pressure lowering) therapy. Baseline plasma levels of C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size did not predict recurrent ischemic stroke risk."

In conclusion the authors write, "Characterization of the mechanisms of ischemic stroke pathogenesis associated with increased sVCAM-1 level may lead to development of therapies that provide benefits additional to those provided by angiotensin-converting enzyme inhibitor-based (ACE-inhibitors), blood pressure lowering therapies."

'"/>

Contact: Duncan J. Campbell, M.D., Ph.D.
dcampbell@svi.edu.au
JAMA and Archives Journals
14-Nov-2005

Page: 1 2
Related medicine news :

1. Biomarkers for psychosis
2. Biomarkers used to predict recurrent disease in hepatitis C transplant patients
3. Biomarkers for interstitial cystitis identified, could lead to the first test
4. Sports concussion research using fMRI provides insight for safe return-to-play decisions
5. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
6. CAM-oriented primary care providers result in cost savings, high patient satisfaction
7. Even when childs cancer prognosis is poor, parent/physician communication can provide hope
8. Tumor cell activity may provide clues for treating breast cancer in young women
9. E/Tablet technology may provide benefits to patients, researchers
10. Daytrana provides significant effectiveness in both boys and girls with ADHD
11. Stem cells provide clues to cancer spread